Literature DB >> 33215260

Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them.

Maryam Zamani Sani1, Afshar Bargahi1, Niloofar Momenzadeh2, Parva Dehghani2, Maryam Vakili Moghadam3, Soheila June Maleki4, Iraj Nabipour2, Afshin Shirkani5, Javad Akhtari6, Khashayar Hesamizadeh7, Sahel Heidari3, Fatemeh Omrani2, Samad Akbarzadeh1, Mohsen Mohammadi8.   

Abstract

Chimeric virus-like particles (VLPs) were developed as a candidate for allergen-specific immunotherapy. In this study, hepatitis B core antigen (HBcAg) that genetically fused to Chenopodium album polcalcin (Che a 3)-derived peptide was expressed in E. coli BL21, purified, and VLP formation was evaluated using native agarose gel electrophoresis (NAGE) and transmission electron microscopy (TEM). Chimeric HBc VLPs were characterized in terms of their reactivity to IgE, the induction of blocking IgG and allergen-specific IgE, basophil-activating capacity, and Th1-type immune responses. Results from IgE reactivity and basophil activation test showed that chimeric HBc VLPs lack IgE-binding capacity and basophil degranulation activity. Although chimeric HBc VLPs induced the highest level of efficient polcalcin-specific IgG antibody in comparison to those induced by recombinant Che a 3 (rChe a 3) mixed either with HBc VLPs or alum, they triggered the lowest level of polcalcin-specific IgE in mice following immunization. Furthermore, in comparison to the other antigens, chimeric HBc VLPs produced a polcalcin-specific Th1 cell response. Taken together, genetically fusion of allergen derivatives to HBc VLPs, in comparison to a mix of them, may be a more effective way to induce appropriate immune responses in allergen-specific immunotherapy. KEY POINTS: • The insertion of allergen-derived peptide into major insertion region (MIR) of hepatitis B virus core (HBc) antigen resulted in nanoparticles displaying allergen-derived peptide upon its expression in prokaryotic host. • The resultant VLPs (chimeric HBc VLPs) did not exhibit IgE reactivity with allergic patients' sera and were not able to degranulate basophils. • Chimeric HBc VLPs dramatically improved protective IgG antibody response compared with those induced by allergen mixed either with HBc VLPs or alum. • Chimeric HBc VLPs induced Th1 responses that were counterparts of Th2 responses (allergic). • Chimeric HBc VLPs increased IgG2a/ IgG1 ratio and the level of IFN-γ compared to those induced by allergen mixed with either HBc VLPs or alum. Graphical Abstract.

Entities:  

Keywords:  Chenopodium album polcalcin; Chimeric viral-like particle; Vaccine design; Virus-like particle

Mesh:

Substances:

Year:  2020        PMID: 33215260     DOI: 10.1007/s00253-020-11012-0

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  52 in total

1.  The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects.

Authors:  C Alexander; M Tarzi; M Larché; A B Kay
Journal:  Allergy       Date:  2005-10       Impact factor: 13.146

2.  Suppression of dust mite allergy by mucosal delivery of a hypoallergenic derivative in a mouse model.

Authors:  Chunqing Ai; Qiuxiang Zhang; Junrong Ding; Chengcheng Ren; Gang Wang; Xiaoming Liu; Fengwei Tian; Jianxin Zhao; Hao Zhang; Yong Q Chen; Wei Chen
Journal:  Appl Microbiol Biotechnol       Date:  2015-02-07       Impact factor: 4.813

3.  Allergens displayed on virus-like particles are highly immunogenic but fail to activate human mast cells.

Authors:  P Engeroff; F Caviezel; F Storni; F Thoms; M Vogel; M F Bachmann
Journal:  Allergy       Date:  2017-09-12       Impact factor: 13.146

4.  Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy.

Authors:  G A Bannon; G Cockrell; C Connaughton; C M West; R Helm; J S Stanley; N King; P Rabjohn; H A Sampson; A W Burks
Journal:  Int Arch Allergy Immunol       Date:  2001 Jan-Mar       Impact factor: 2.749

5.  Incorporation of T-cell epitopes from tetanus and diphtheria toxoids into in-silico-designed hypoallergenic vaccine may enhance the protective immune response against allergens.

Authors:  Ali Ghasemi; Reza Falak; Mohsen Mohammadi; Soheila June Maleki; Mohamad-Ali Assarezadegan; Mojtaba Jafary
Journal:  Iran J Basic Med Sci       Date:  2020-05       Impact factor: 2.699

6.  The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.

Authors:  Kai-Michael Beeh; Frank Kanniess; Frank Wagner; Cordula Schilder; Ingomar Naudts; Anya Hammann-Haenni; Joerg Willers; Hans Stocker; Philipp Mueller; Martin F Bachmann; Wolfgang A Renner
Journal:  J Allergy Clin Immunol       Date:  2013-02-04       Impact factor: 10.793

Review 7.  Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report.

Authors:  A Wesley Burks; Moises A Calderon; Thomas Casale; Linda Cox; Pascal Demoly; Marek Jutel; Harold Nelson; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2013-03-14       Impact factor: 10.793

8.  Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines.

Authors:  Ariane C Gomes; Anna Flace; Philippe Saudan; Franziska Zabel; Gustavo Cabral-Miranda; Aadil El Turabi; Vania Manolova; Martin F Bachmann
Journal:  Front Immunol       Date:  2017-03-06       Impact factor: 7.561

Review 9.  Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches.

Authors:  Mirela Curin; Musa Khaitov; Alexander Karaulov; Leyla Namazova-Baranova; Raffaela Campana; Victoria Garib; Rudolf Valenta
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-09       Impact factor: 4.806

Review 10.  Virus-Like Particles as Carrier Systems to Enhance Immunomodulation in Allergen Immunotherapy.

Authors:  Martina Anzaghe; Stefan Schülke; Stephan Scheurer
Journal:  Curr Allergy Asthma Rep       Date:  2018-10-25       Impact factor: 4.919

View more
  1 in total

Review 1.  Virus-like particle vaccinology, from bench to bedside.

Authors:  Mona O Mohsen; Martin F Bachmann
Journal:  Cell Mol Immunol       Date:  2022-08-12       Impact factor: 22.096

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.